Wild mice presumably serve as the main reservoir of infection and must be excluded from laboratory animal facilities (Lussier et al., 1988a). Periodic health surveillance testing of mouse stocks by ELISA is recommended (Lussier et al., 1988a,b). Elimination of the virus from infected mouse stocks might be possible through isolation of breeding pairs, with selection of progeny by ELISA testing (Lussier et al., 1988a,b) and passage of tissues in neonatal mice to test for development of lymphoid necrosis in thymus, lymph nodes, and spleen (Morse, 1987).

The passage of tissues from mice subclinically infected with MTV in neonatal mice may be inadvertently complicated by the effects of this virus (Rose and Capps, 1961).

High.

1961: Innes and Stanton (1961) reported two epizootics in which weanling rats had swollen, thickened necks and red porphyrin pigment along the eyelid margins. Microscopically, there was severe inflammation and edema of the submaxillary salivary glands and Harderian glands (other lacrimal glands were not examined), and the disease was named sialodacryoadenitis. A viral etiology was suspected but virus isolation was not attempted.

1963: Hunt (1963) reported a disease in young rats from two shipments. Ten days after receipt, many of the rats had suborbital swelling and conjunctivitis, and a few had keratitis with corneal ulceration. The Harderian and intraorbital lacrimal glands were twice the normal size and were histologically characterized by loss of glandular tissue, hyperplasia and squamous metaplasia of the ductal epithelium, intense histiocytic inflammation, and acidophilic intranuclear inclusions in occasional epithelial cells. The disease was called dacryoadenitis.

1969: Jonas et al. (1969) reproduced the disease of salivary and lacrimal glands by intranasally inoculating gnotobiotic rats with an ultrafiltrate of the submaxillary gland from a rat with sialodacryoadenitis.

1970: Parker et al. (1970c) isolated and characterized a virus from the lungs of laboratory rats with mild interstitial pneumonia, carried out experi-

Front Matter (R1-R12)

I. Principles of Rodent Disease Prevention (1-2)

1. Objectives, Terminology, and Overview of Pathogen Status (3-12)

2. Breeding, Transportation, and Use of Pathogen-Free Rodents (13-16)

3. Barrier Programs (17-20)

4. Health Surveillance Programs (21-28)

II. Individual Disease Agents and Their Effects on Research (29-30)

5. Introduction (31-32)

6. Respiratory System (33-84)

7. Digestive System (85-163)

8. Skin and Joints (164-197)

9. Hemopoietic System (198-221)

10. Central Nervous System (222-230)

11. Genitourinary System (231-235)

12. Multiple Systems (236-256)

III. Indexes to Diagnosis and Research Complications of Infectious Agents (257-258)

Introduction (259-259)

Clinical Signs (260-265)

Pathology (266-274)

Research Complications (275-276)

References (277-386)

Index (387-397)